Comparison · NCT01234350-sae
FIRMAGON vs GnRH Agonist: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. FIRMAGON vs GnRH Agonist: serious adverse events. Trial comparisons, record NCT01234350-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01234350-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.236 | 0.211 | 0.263 | wilson | |
| Risk in group 2 | 0.292 | 0.254 | 0.334 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0561 | -0.105 | -0.00897 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.808 | 0.677 | 0.964 | log | |
| Odds ratio, group 1 over group 2 | 0.749 | 0.587 | 0.954 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on FIRMAGON than on GnRH Agonist | 17.8 | 9.54 | 112 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | FIRMAGON | FIRMAGON (Degarelix, a GnRH antagonist) was prescribed in accordance with the approved label | 236 | 1,000 | EG000 |
| Group 2 | GnRH Agonist | Any GnRH agonist prescribed in accordance with the approved labels | 144 | 493 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From baseline upto 5 years (every 3 months from the first 2 years of the study; every 6 months for the last 3 years of the study)
Source ClinicalTrials.gov
Trial
- Title
- A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
- NCT number
- NCT01234350
- Phases
- Conditions
- Prostate Cancer
- Interventions
- Lead sponsor
- Ferring Pharmaceuticals
- Results first posted
- 2019-05-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01234350?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01234350-sae